Antifungal Drugs are used for treating common fungal infections such as fungal nail infection, vaginal infection and others that appear on the external surface of the body and other fungal invasive infection that occur inside the tissue of the body or in an internal organ such as lungs and brains. It works against the fungal infection by either killing the fungal cells or by constraining their growth.
The global Antifungal Drugs market is expected to reach US$ 13,524.2 Mn in 2027 from US$ 10,182.3 Mn in 2018. The market is estimated to grow with a CAGR of 3.2% from 2019-2027. The market is likely to grow due to the rising incidences for the fungal infection of the skin, nails and hair, increasing incidences of cancers, HIV, and hospital-acquired infections and favorable government initiatives to combat the antifungal diseases.
Get Sample Copy with Complete TOC and Figures & Graphs @ https://www.theinsightpartners.com/sample/TIPRE00003745/
The market has experienced few organic strategies such as product launch, product approval and expansion activities that also has resulted positively for the growth of the market. The companies have also conducted lot of inorganic strategies such as partnership, acquisitions and agreements that has enhance the product portfolio.
Azoles is expected to drive the growth of the global Antifungal Drugs market by drug type segment
The most notable market participants are Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Merck And Co., Inc., Scynexis Inc., Novartis International AG, Abbott Laboratories, Bayer AG, Glenmark Pharmaceutical, and Glaxosmithkline Plc. among the others have occupied a considerable share of the market owing to their product offerings to the companies.
Have a Question? Speak to Research Expert: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00003745/
Market leaders are involved in organic and inorganic growth strategies in the antifungal drugs market. For instance, the companies have maximized their growth with several inorganic strategies to enhance the market value and position in the market. The inorganic developments in the market were maximum among the development in the antifungal drugs.
Below is the list of the inorganic and organic strategies done by the players operating in the antifungal drugs market:
| Year | News | Region |
| May, 2019 | Merck and P&G signed an agreement to sale 51.80% stake of Merck Limited to P&G promoters at value of INR 1,290.19 crore. According to the agreement, Merck would be renamed as Procter and Gamble Health Ltd | Asia Pacific |
| September, 2018 | Aurobindo’s acquired generic dermatology portfolio of Novartis US which would include a wide range of therapeutic areas, including topical antibiotics, gynaecological and dermatological anti-fungal agents, anti-acne agents, local anaesthetic analgesics, anti-itch, and a dermatological chemotherapeutic agent. | North America |
| November, 2017 | Merck & Co., Inc. declared that the U.S. Food and Drug Administration (FDA) approved PREVYMIS (letermovir) to be uses as once-daily tablets for oral use and injection for intravenous infusion. | North America |
Purchase a Copy of this Report: https://www.theinsightpartners.com/buy/TIPRE00003745/
About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, chemicals etc.
Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com
